340 related articles for article (PubMed ID: 30214620)
1. Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.
Di Lorenzo G; Ricci G; Severini GM; Romano F; Biffi S
Theranostics; 2018; 8(16):4279-4294. PubMed ID: 30214620
[TBL] [Abstract][Full Text] [Related]
2. Theranostic Nanostructures for Ovarian Cancer.
Navyatha B; Nara S
Crit Rev Ther Drug Carrier Syst; 2019; 36(4):305-371. PubMed ID: 31679190
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable nanoparticles as theranostics of ovarian cancer: an overview.
Chaurasiya S; Mishra V
J Pharm Pharmacol; 2018 Apr; 70(4):435-449. PubMed ID: 29380366
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.
Hoosen Y; Pradeep P; Kumar P; du Toit LC; Choonara YE; Pillay V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510526
[TBL] [Abstract][Full Text] [Related]
5. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
7. In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers.
Patel NR; Piroyan A; Ganta S; Morse AB; Candiloro KM; Solon AL; Nack AH; Galati CA; Bora C; Maglaty MA; O'Brien SW; Litwin S; Davis B; Connolly DC; Coleman TP
Cancer Biol Ther; 2018 Jul; 19(7):554-564. PubMed ID: 29737910
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience.
Carmignani CP; Sugarbaker PH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):477-87. PubMed ID: 15161446
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a CEACAM6-targeting theranostic nanomedicine for photoacoustic-based diagnosis and chemotherapy of metastatic cancer.
Lee H; Jang Y; Park S; Jang H; Park EJ; Kim HJ; Kim H
Theranostics; 2018; 8(15):4247-4261. PubMed ID: 30128051
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy.
Gao M; Yu F; Lv C; Choo J; Chen L
Chem Soc Rev; 2017 Apr; 46(8):2237-2271. PubMed ID: 28319221
[TBL] [Abstract][Full Text] [Related]
11. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches.
Bejarano J; Navarro-Marquez M; Morales-Zavala F; Morales JO; Garcia-Carvajal I; Araya-Fuentes E; Flores Y; Verdejo HE; Castro PF; Lavandero S; Kogan MJ
Theranostics; 2018; 8(17):4710-4732. PubMed ID: 30279733
[TBL] [Abstract][Full Text] [Related]
13. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.
Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y
Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815
[No Abstract] [Full Text] [Related]
14. Recent progress in nanomedicine for enhanced cancer chemotherapy.
Wei G; Wang Y; Yang G; Wang Y; Ju R
Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
[TBL] [Abstract][Full Text] [Related]
15. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?
Garces ÁH; Dias MS; Paulino E; Ferreira CG; de Melo AC
Cancer Chemother Pharmacol; 2015 Feb; 75(2):221-34. PubMed ID: 25212538
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Nanoparticles in Cancer Theranostics.
Gobbo OL; Sjaastad K; Radomski MW; Volkov Y; Prina-Mello A
Theranostics; 2015; 5(11):1249-63. PubMed ID: 26379790
[TBL] [Abstract][Full Text] [Related]
18. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in ovarian cancer.
Lim HJ; Ledger W
Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
[TBL] [Abstract][Full Text] [Related]
20. Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.
Ferrara B; Belbekhouche S; Habert D; Houppe C; Vallée B; Bourgoin-Voillard S; Cohen JL; Cascone I; Courty J
Nanotechnology; 2021 May; 32(32):. PubMed ID: 33892482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
